Stock NRSN NEUROSENSE THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases NeuroSense Therapeutics Ltd.

Equities

NRSN

IL0011809592

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.23 USD -2.38% Intraday chart for NeuroSense Therapeutics Ltd. -13.38% +56.69%
Apr. 22 NeuroSense to Collaborate With Genetika+ on Alzheimer's Disease Drug Development; Shares Fall MT
Apr. 22 NeuroSense Therapeutics Ltd. and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
PR
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
AQ
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
AQ
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
PR
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
PR
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
AQ
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
PR
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
PR
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
PR
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
PR
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
PR
NeuroSense Reports New Data, Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
AQ
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
PR
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability and Secondary Clinical Efficacy Endpoints
AQ
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability and Secondary Clinical Efficacy Endpoints on December 5, 2023
AQ
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
PR
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
PR
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
PR
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
PR
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRSN Stock
  4. News NeuroSense Therapeutics Ltd.
  5. Press Releases